P-Nitrophenol

P-Nitrophenol

SCHEMBL324522

NC(=O)O.O=[N+]([O-])c1ccc(O)cc1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.61
TDP1 Q9NUW8 1/20 0.57
LMNA P02545 2/20 0.55
GAA P10253 1/20 0.55
CES1 P23141 2/20 0.54
ALDH1A1 P00352 3/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CES2 O00748 1/20 0.52
PLAU P00749 1/20 0.52
SRD5A2 P31213 1/20 0.52
NOS1 P29475 2/20 0.50
MAPK1 P28482 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP19A1 P11511 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Nitrophenol SCHEMBL309332 0.91 TDP1 (0.61) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL14125735 0.91 TDP1 (0.61) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL27462973 0.91 TDP1 (0.60) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL17289474 0.89 TDP1 (0.59) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL15203620 0.89 ALDH1A1 (0.64) TSHRTDP1LMNACES1ALDH1A1
P-Nitrophenol SCHEMBL11048842 0.89 CES1 (0.58) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL1839 0.89 CES1 (0.58) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL29806213 0.89 CES1 (0.58) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL692178 0.87 MAPK1 (0.61) TSHRTDP1LMNAGAACES1
P-Nitrophenol SCHEMBL64459 0.87 ALDH1A1 (0.61) TSHRTDP1LMNACES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435090-B2 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use REPARE THERAPEUTICS INC. (CA) 2025-10-07 US disclosed
US-12116343-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-15 US disclosed
CN-116348447-A Inhibitors of APOL1 and methods of using the same 弗特克斯药品有限公司 2023-06-27 CN disclosed
US-20230122909-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE REPARE THERAPEUTICS INC. (CA) 2023-04-20 US disclosed
EP-4097083-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2022-12-07 EP disclosed
US-20220340523-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 US disclosed
WO-2021154997-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-08-05 WO disclosed
US-20190117680-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2019-04-25 US disclosed
US-20170080097-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2017-03-23 US disclosed
CN-104011021-B heterocyclic derivatives and their use as prostaglandin D2 receptor modulators 埃科特莱茵药品有限公司 2016-08-24 CN disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed
WO-2011030139-A1 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS ASTRAZENECA AB (SE) 2011-03-17 WO disclosed
US-20110065706-A1 Therapeutic Agents 812 ASTRAZENECA AB (SE) 2011-03-17 US disclosed
US-20100105857-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) 2010-04-29 US disclosed
EP-2081601-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS Ariel-University Research And Development Company, Ltd. (IL) 2009-07-29 EP disclosed
WO-2008047345-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2008-04-24 WO disclosed
US-7183319-B2 Phenylethylamine derivatives and their use in the treatment of melanoma RILEY PATRICK ANTHONY 2007-02-27 US disclosed
US-20040029967-A1 Phenylethylamine derivatives and their use in the treatment of melanoma RILEY PATRICK ANTHONY (GB) 2004-02-12 US disclosed
EP-1303481-A1 PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA Riley, Patrick Anthony (GB) 2003-04-23 EP disclosed
WO-2002008174-A1 PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA RILEY PATRICK ANTHONY (GB) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340523-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 TSHR 3789/4885TDP1 1982/4885LMNA 1071/4885
US-12116343-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 TSHR 3789/4885TDP1 1982/4885LMNA 1071/4885
US-20230122909-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE PLK1, CSNK1A1, CSNK1G1 TSHR 2951/4885TDP1 677/4885LMNA 2090/4885
US-20190117680-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS CCL2, CD63, CD69 TSHR 1614/4885TDP1 4335/4885LMNA 2024/4885
US-12435090-B2 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use PLK1, CSNK1A1, CSNK1G1 TSHR 2951/4885TDP1 677/4885LMNA 2090/4885
US-20110065706-A1 Therapeutic Agents 812 GPR119, GPR84, GPR132 TSHR 957/4885TDP1 4678/4885LMNA 4102/4885
US-20170080097-A1 DENDRIMERIC PLATFORM FOR CONTROLLED RELEASE OF DRUGS CCL2, CD63, CD69 TSHR 1614/4885TDP1 4335/4885LMNA 2024/4885
US-20040029967-A1 Phenylethylamine derivatives and their use in the treatment of melanoma DOHH, DBH, HRH4 TSHR 538/4885TDP1 2119/4885LMNA 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.